What is HC Wainwright’s Forecast for LENZ Q3 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of LENZ Therapeutics in a note issued to investors on Thursday, November 6th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.58) for the quarter. HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2026 earnings at ($0.41) EPS and FY2029 earnings at $1.84 EPS.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.08. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $4.64 million.

Several other equities research analysts also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Wednesday, October 8th. Citigroup reaffirmed a “buy” rating and issued a $49.00 target price (up from $45.00) on shares of LENZ Therapeutics in a research note on Thursday, July 31st. Piper Sandler increased their target price on LENZ Therapeutics to $67.00 and gave the company an “overweight” rating in a research note on Friday, October 10th. Raymond James Financial reissued an “outperform” rating and issued a $50.00 target price (up from $40.00) on shares of LENZ Therapeutics in a research note on Monday, October 20th. Finally, Zacks Research raised LENZ Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $56.40.

LENZ Therapeutics Stock Performance

Shares of LENZ traded down $0.48 during mid-day trading on Friday, hitting $22.48. The company’s stock had a trading volume of 390,275 shares, compared to its average volume of 442,922. LENZ Therapeutics has a one year low of $16.53 and a one year high of $50.40. The stock’s 50-day moving average is $38.70 and its two-hundred day moving average is $33.84. The firm has a market capitalization of $641.02 million, a PE ratio of -10.64 and a beta of 0.46.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LENZ. Vanguard Group Inc. raised its stake in LENZ Therapeutics by 3.0% during the third quarter. Vanguard Group Inc. now owns 1,330,286 shares of the company’s stock worth $61,965,000 after buying an additional 39,292 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of LENZ Therapeutics by 8.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,222 shares of the company’s stock worth $523,000 after buying an additional 861 shares during the period. Aberdeen Group plc increased its stake in shares of LENZ Therapeutics by 76.0% in the 3rd quarter. Aberdeen Group plc now owns 130,726 shares of the company’s stock valued at $6,089,000 after acquiring an additional 56,440 shares in the last quarter. Rhumbline Advisers lifted its position in shares of LENZ Therapeutics by 2.7% during the 3rd quarter. Rhumbline Advisers now owns 25,019 shares of the company’s stock valued at $1,165,000 after acquiring an additional 656 shares during the period. Finally, Profund Advisors LLC bought a new stake in LENZ Therapeutics in the third quarter valued at $223,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.